Profile | GDS2987 / GI_21237796-I |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 14.3 | 45 |
GSM215244 | HMVEC_vehicle_rep2 | 5.7 | 15 |
GSM215253 | HMVEC_vehicle_rep3 | 0.6 | 2 |
GSM215254 | HMVEC_atorvastatin_rep1 | 44.5 | 67 |
GSM215282 | HMVEC_atorvastatin_rep3 | 10.5 | 25 |
GSM215344 | HMVEC_atorvastatin_rep2 | 23.9 | 50 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 10.2 | 21 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 11.8 | 20 |
GSM215294 | HMVEC_SLx2119_rep1 | 23.5 | 60 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 3 | 5 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 48.3 | 58 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 26.6 | 43 |
GSM215312 | PASMC_atorvastatin_rep2 | 23.4 | 36 |
GSM215313 | PASMC_atorvastatin_rep3 | 16.7 | 25 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 26.8 | 42 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 20.9 | 35 |
GSM215328 | PASMC_SLx2119_rep2 | 3 | 6 |
GSM215329 | PASMC_SLx2119_rep3 | 7 | 14 |
GSM215330 | Fibroblasts_vehicle_rep1 | 2 | 5 |
GSM215331 | Fibroblasts_vehicle_rep2 | 22.2 | 51 |
GSM215332 | Fibroblasts_vehicle_rep3 | 8.8 | 29 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 11 | 29 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 18.6 | 46 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 7.5 | 25 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 1.9 | 6 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 1.6 | 5 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 3.8 | 11 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 18.9 | 47 |
GSM215341 | Fibroblasts_SLx2119_rep3 |